Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are
standard of care for patients with EGFR mutation-positive non–small-cell lung cancer …
standard of care for patients with EGFR mutation-positive non–small-cell lung cancer …
Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC
M Takeda, I Okamoto, J Tsurutani, N Oiso… - Japanese journal of …, 2012 - academic.oup.com
Objective Somatic mutations in the epidermal growth factor receptor gene are associated
with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors …
with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors …
The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations
GJ Riely - Lung Cancer, 2008 - Elsevier
Initial studies with the first-generation epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors gefitinib and erlotinib in patients with non-small cell lung cancer (NSCLC) …
kinase inhibitors gefitinib and erlotinib in patients with non-small cell lung cancer (NSCLC) …
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non–small cell lung cancer patients treated with gefitinib or …
DM Jackman, BY Yeap, LV Sequist, N Lindeman… - Clinical Cancer …, 2006 - AACR
Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) have been
detected in patients with non–small cell lung cancer (NSCLC) and are associated with …
detected in patients with non–small cell lung cancer (NSCLC) and are associated with …
The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer …
Background Epidermal growth factor receptor (EGFR) mutations are associated with
sensitivity to gefitinib or erlotinib in non-small cell lung cancer (NSCLC). We investigated the …
sensitivity to gefitinib or erlotinib in non-small cell lung cancer (NSCLC). We investigated the …
Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?
JY Lee, SH Lim, M Kim, S Kim, HA Jung… - Cancer chemotherapy …, 2014 - Springer
Abstract Background Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor
receptor (EGFR) have demonstrated some dramatic response rate and prolonged …
receptor (EGFR) have demonstrated some dramatic response rate and prolonged …
Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
D Chen, Z Song, G Cheng - OncoTargets and therapy, 2016 - Taylor & Francis
Purpose Subsets of non-small-cell lung cancer patients with epidermal growth factor
receptor (EGFR) mutations carry uncommon subtypes. We evaluated the efficacy of first …
receptor (EGFR) mutations carry uncommon subtypes. We evaluated the efficacy of first …
Clinicopathologic characteristics and outcome of patients with different EGFR mutations
S Zhou, X Hu, Y Wang, J Li, L Zhou… - Asia‐Pacific Journal …, 2019 - Wiley Online Library
Aim Most epidermal growth factor receptor (EGFR) gene mutations affecting exon 19
(inframe deletions; 19 Del) and 21 (L858R), while the rest (referred as uncommon EGFR …
(inframe deletions; 19 Del) and 21 (L858R), while the rest (referred as uncommon EGFR …
Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study
M Kanazu, M Mori, M Kimura, K Nishino… - Thoracic …, 2021 - Wiley Online Library
Background Epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) therapy
is the standard treatment for advanced non‐small cell lung cancer (NSCLC) harboring …
is the standard treatment for advanced non‐small cell lung cancer (NSCLC) harboring …
Impact of smoking history on the efficacy of gefitinib in patients with non-small cell lung cancer harboring activating epidermal growth factor receptor mutations
S Igawa, J Sasaki, S Otani, M Ishihara, A Takakura… - Oncology, 2015 - karger.com
Background: Gefitinib treatment has come to be recognized as the standard therapy for
patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor …
patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor …